QRX-3

**QRX-3** is an investigational renal therapeutic developed by Neukidney for chronic kidney disease and acute kidney injury, including acute tubular necrosis. It is also reported in a registered study as **Eseronate**. Registry descriptions characterize QRX-3 as a formulated NAD/NAD+ redox and mitochondrial oxidative-phosphorylation modulator intended to increase mitochondrial NAD+ availability in renal tubular cells, reduce oxidative and fibrogenic injury, and preserve nephron function. Its precise chemical composition, molecular structure, direct binding target, dosage form, and route of administration have not been publicly disclosed. The proposed biology is sponsor/investigator-described and has not been independently established as a defined molecular pharmacology. ([neukidney.com](https://www.neukidney.com/qrx3))

Other names

Eseronate